Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click

Jessica Ward1, Samantha N Spath, Brandon Pabst

  • 1Cardiovascular and Metabolic Diseases Research Unit and ‡Medicinal Chemistry, Pfizer Worldwide Research and Development , Cambridge, Massachusetts 02139, United States.

Biochemistry
|December 11, 2013
PubMed

Insights

A novel myeloperoxidase (MPO) inhibitor, compound A, acts as a mechanism-based inactivator. However, its activated form can modify other proteins, highlighting the need for next-generation MPO inhibitors.

Area of Science:

  • Biochemistry
  • Pharmacology

Background:

  • Myeloperoxidase (MPO) is a key enzyme in inflammation, making it a therapeutic target.
  • Developing effective MPO inhibitors for pharmacological studies remains challenging.

Purpose of the Study:

  • To mechanistically characterize the MPO inhibitor 2-Thioxanthine, 3-(2-ethoxypropyl)-2-thioxo-2,3-dihydro-1H-purin-6(9H)-one (A).
  • To assess the selectivity and potential off-target effects of compound A.

Main Methods:

  • Kinetic analysis of MPO inactivation by compound A.
  • Assessing MPO catalysis dependence and substrate protection.
  • Utilizing click chemistry-activity-based protein profiling to identify labeled proteins.

Main Results:

  • Compound A is a time-dependent, mechanism-based MPO inactivator with a potency (k(inact)/K(I)) of 8450 ± 780 M⁻¹ s⁻¹.
  • The MPO-activated inhibitory species of A can diffuse and covalently modify other proteins, with a partition ratio of 15.6.
  • Compound A exhibits high selectivity against over 100 other targets but labels multiple proteins in the presence of MPO.

Conclusions:

  • Compound A's mechanism-based inactivation of MPO is confirmed.
  • The potential for off-target protein modification by the activated inhibitor necessitates careful consideration in drug development.
  • This study provides insights for designing improved MPO inhibitors with enhanced specificity.

Related Concept Videos